Goldman Sachs Group Inc. Boosts Holdings in Ophthotech Corporation (OPHT)

Goldman Sachs Group Inc. raised its position in shares of Ophthotech Corporation (NASDAQ:OPHT) by 28.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 652,992 shares of the biopharmaceutical company’s stock after acquiring an additional 143,349 shares during the period. Goldman Sachs Group Inc. owned approximately 1.82% of Ophthotech Corporation worth $1,672,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Stonepine Capital Management LLC grew its position in Ophthotech Corporation by 1.7% during the second quarter. Stonepine Capital Management LLC now owns 3,576,189 shares of the biopharmaceutical company’s stock valued at $9,155,000 after acquiring an additional 59,700 shares during the period. Tamarack Advisers LP grew its position in Ophthotech Corporation by 32.7% during the second quarter. Tamarack Advisers LP now owns 625,000 shares of the biopharmaceutical company’s stock valued at $1,600,000 after acquiring an additional 153,851 shares during the period. Federated Investors Inc. PA grew its position in Ophthotech Corporation by 102.3% during the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 28,040 shares during the period. LMR Partners LLP purchased a new stake in Ophthotech Corporation during the second quarter valued at about $269,000. Finally, Canada Pension Plan Investment Board grew its position in Ophthotech Corporation by 97.9% during the second quarter. Canada Pension Plan Investment Board now owns 260,600 shares of the biopharmaceutical company’s stock valued at $667,000 after acquiring an additional 128,900 shares during the period. 61.32% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2017/11/02/goldman-sachs-group-inc-boosts-holdings-in-ophthotech-corporation-opht.html.

A number of equities research analysts have issued reports on the company. ValuEngine raised Ophthotech Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Stifel Nicolaus reissued a “hold” rating and set a $4.00 price target on shares of Ophthotech Corporation in a research report on Thursday, September 21st. Twelve analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $25.00.

Ophthotech Corporation Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Want to see what other hedge funds are holding OPHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ophthotech Corporation (NASDAQ:OPHT).

Institutional Ownership by Quarter for Ophthotech Corporation (NASDAQ:OPHT)

What are top analysts saying about Ophthotech Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ophthotech Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit